# REGENXBIO Inc.: financial statements, quarterly

RGNX · Nasdaq · CIK 1590877 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rgnx.md) · [Financials](/companies/rgnx/financials.md) · [Filings](/companies/rgnx/filings.md) · [Insiders](/companies/rgnx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rgnx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [28.9](/filings/0000950170-24-122330.md) | [22.2 d](/filings/0000950170-25-038770.md) | [15.6](/filings/0000950170-25-069237.md) | [22.3](/filings/0001193125-25-174953.md) | [24.2](/filings/0001193125-25-268095.md) | [21.2 d](/filings/0001193125-26-094013.md) | [89.0](/filings/0001193125-26-222804.md) | [21.4](/filings/0001193125-26-336725.md) | [29.7](/filings/0001193125-25-268095.md) | [30.3 d](/filings/0001193125-26-094013.md) | [6.4](/filings/0001193125-26-222804.md) | [108](/filings/0001193125-26-336725.md) |
| Cost of revenue | $m | [12.4](/filings/0000950170-24-122330.md) | [11.2 d](/filings/0000950170-25-038770.md) | [4.3](/filings/0000950170-24-055691.md) | [10.6](/filings/0000950170-24-089320.md) | [12.4](/filings/0000950170-24-122330.md) | [6.3 d](/filings/0000950170-25-038770.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [58.2](/filings/0000950170-24-122330.md) | [55.7 d](/filings/0000950170-25-038770.md) | [54.8](/filings/0000950170-25-069237.md) | [48.9](/filings/0001193125-25-174953.md) | [54.4](/filings/0001193125-25-268095.md) | [50.4 d](/filings/0001193125-26-094013.md) | [53.1](/filings/0001193125-26-222804.md) | [59.5](/filings/0001193125-26-336725.md) | [56.1](/filings/0001193125-25-268095.md) | [59.6 d](/filings/0001193125-26-094013.md) | [57.3](/filings/0001193125-26-222804.md) | [56.1](/filings/0001193125-26-336725.md) |
| Operating income | $m | [(65.0)](/filings/0000950170-24-122330.md) | [(63.9) d](/filings/0000950170-25-038770.md) | [(63.9)](/filings/0000950170-25-069237.md) | [(56.0)](/filings/0001193125-25-174953.md) | [(62.1)](/filings/0001193125-25-268095.md) | [(51.4) d](/filings/0001193125-26-094013.md) | [12.1](/filings/0001193125-26-222804.md) | [(63.3)](/filings/0001193125-26-336725.md) | [(52.4)](/filings/0001193125-25-268095.md) | [(57.6) d](/filings/0001193125-26-094013.md) | [(83.4)](/filings/0001193125-26-222804.md) | [29.3](/filings/0001193125-26-336725.md) |
| Interest expense | $m | [1.6](/filings/0000950170-23-061144.md) | [1.4 d](/filings/0000950170-24-021161.md) | [2.0](/filings/0000950170-24-055691.md) | [0.4](/filings/0000950170-24-089320.md) | [0.8](/filings/0001193125-25-268095.md) | [9.4 d](/filings/0001193125-26-094013.md) | [8.6](/filings/0001193125-26-222804.md) | [11.0](/filings/0001193125-26-336725.md) | [13.2](/filings/0001193125-25-268095.md) | [12.3 d](/filings/0001193125-26-094013.md) | [8.7](/filings/0001193125-26-222804.md) | [7.8](/filings/0001193125-26-336725.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(61.9)](/filings/0000950170-24-122330.md) | [(62.9) d](/filings/0000950170-25-038770.md) | [(63.3)](/filings/0000950170-25-069237.md) | [(53.0)](/filings/0001193125-25-174953.md) | [(59.6)](/filings/0001193125-25-268095.md) | [(51.2) d](/filings/0001193125-26-094013.md) | [6.1](/filings/0001193125-26-222804.md) | [(70.9)](/filings/0001193125-26-336725.md) | [(61.9)](/filings/0001193125-25-268095.md) | [(67.1) d](/filings/0001193125-26-094013.md) | [(90.1)](/filings/0001193125-26-222804.md) | [22.7](/filings/0001193125-26-336725.md) |
| Diluted EPS | $ per share | [(1.41)](/filings/0000950170-24-122330.md) | not reported | [(1.38)](/filings/0000950170-25-069237.md) | [(1.05)](/filings/0001193125-25-174953.md) | [(1.17)](/filings/0001193125-25-268095.md) | not reported | [0.12](/filings/0001193125-26-222804.md) | [(1.38)](/filings/0001193125-26-336725.md) | [(1.20)](/filings/0001193125-25-268095.md) | not reported | [(1.72)](/filings/0001193125-26-222804.md) | [0.43](/filings/0001193125-26-336725.md) |
| Basic EPS | $ per share | [(1.41)](/filings/0000950170-24-122330.md) | not reported | [(1.38)](/filings/0000950170-25-069237.md) | [(1.05)](/filings/0001193125-25-174953.md) | [(1.17)](/filings/0001193125-25-268095.md) | not reported | [0.12](/filings/0001193125-26-222804.md) | [(1.38)](/filings/0001193125-26-336725.md) | [(1.20)](/filings/0001193125-25-268095.md) | not reported | [(1.72)](/filings/0001193125-26-222804.md) | [0.43](/filings/0001193125-26-336725.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [53.0](/filings/0000950170-24-122330.md) | [34.5](/filings/0000950170-25-038770.md) | [113](/filings/0000950170-25-069237.md) | [57.8](/filings/0001193125-25-174953.md) | [56.6](/filings/0001193125-25-268095.md) | [57.5](/filings/0001193125-26-094013.md) | [130](/filings/0001193125-26-222804.md) | [79.6](/filings/0001193125-26-336725.md) | [58.8](/filings/0001193125-25-268095.md) | [34.5](/filings/0001193125-26-336725.md) | [15.2](/filings/0001193125-26-222804.md) | [36.5](/filings/0001193125-26-336725.md) |
| Current assets | $m | [366](/filings/0000950170-23-061144.md) | [335](/filings/0000950170-25-038770.md) | [395](/filings/0000950170-24-055691.md) | [347](/filings/0000950170-24-089320.md) | [313](/filings/0000950170-24-122330.md) | [278](/filings/0001193125-26-094013.md) | [313](/filings/0000950170-25-069237.md) | [374](/filings/0001193125-25-174953.md) | [332](/filings/0001193125-25-268095.md) | [281](/filings/0001193125-26-336725.md) | [187](/filings/0001193125-26-222804.md) | [236](/filings/0001193125-26-336725.md) |
| Total assets | $m | [634](/filings/0000950170-23-061144.md) | [574](/filings/0000950170-25-038770.md) | [629](/filings/0000950170-24-055691.md) | [569](/filings/0000950170-24-089320.md) | [519](/filings/0000950170-24-122330.md) | [466](/filings/0001193125-26-094013.md) | [491](/filings/0000950170-25-069237.md) | [581](/filings/0001193125-25-174953.md) | [525](/filings/0001193125-25-268095.md) | [453](/filings/0001193125-26-336725.md) | [342](/filings/0001193125-26-222804.md) | [387](/filings/0001193125-26-336725.md) |
| Current liabilities | $m | [127](/filings/0000950170-23-061144.md) | [130](/filings/0000950170-25-038770.md) | [110](/filings/0000950170-24-055691.md) | [98.3](/filings/0000950170-24-089320.md) | [103](/filings/0000950170-24-122330.md) | [103](/filings/0001193125-26-094013.md) | [107](/filings/0000950170-25-069237.md) | [120](/filings/0001193125-25-174953.md) | [125](/filings/0001193125-25-268095.md) | [118](/filings/0001193125-26-336725.md) | [71.1](/filings/0001193125-26-222804.md) | [82.6](/filings/0001193125-26-336725.md) |
| Total liabilities | $m | [271](/filings/0000950170-23-061144.md) | [262](/filings/0000950170-25-038770.md) | [239](/filings/0000950170-24-055691.md) | [221](/filings/0000950170-24-089320.md) | [218](/filings/0000950170-24-122330.md) | [206](/filings/0001193125-26-094013.md) | [217](/filings/0000950170-25-069237.md) | [367](/filings/0001193125-25-174953.md) | [364](/filings/0001193125-25-268095.md) | [350](/filings/0001193125-26-336725.md) | [321](/filings/0001193125-26-222804.md) | [315](/filings/0001193125-26-336725.md) |
| Shareholders' equity | $m | [363](/filings/0000950170-24-122330.md) | [312](/filings/0001193125-26-094013.md) | [391](/filings/0001193125-25-174953.md) | [348](/filings/0001193125-25-268095.md) | [301](/filings/0001193125-25-268095.md) | [260](/filings/0001193125-26-336725.md) | [274](/filings/0001193125-26-336725.md) | [214](/filings/0001193125-26-336725.md) | [161](/filings/0001193125-25-268095.md) | [103](/filings/0001193125-26-336725.md) | [21.1](/filings/0001193125-26-336725.md) | [71.8](/filings/0001193125-26-336725.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(49.4) d](/filings/0000950170-24-122330.md) | [(40.8) d](/filings/0000950170-25-038770.md) | [(55.5)](/filings/0000950170-25-069237.md) | [(45.5) d](/filings/0001193125-25-174953.md) | [(40.5) d](/filings/0001193125-25-268095.md) | [(31.6) d](/filings/0001193125-26-094013.md) | [33.6](/filings/0001193125-26-222804.md) | [(49.3) d](/filings/0001193125-26-336725.md) | [(56.0) d](/filings/0001193125-25-268095.md) | [(52.3) d](/filings/0001193125-26-094013.md) | [(76.2)](/filings/0001193125-26-222804.md) | [(62.2) d](/filings/0001193125-26-336725.md) |
| Capital expenditure | $m | [1.4 d](/filings/0000950170-24-122330.md) | [1.1 d](/filings/0000950170-25-038770.md) | [0.6](/filings/0000950170-25-069237.md) | [0.5 d](/filings/0001193125-25-174953.md) | [0.3 d](/filings/0001193125-25-268095.md) | [1.1 d](/filings/0001193125-26-094013.md) | [1.0](/filings/0001193125-26-222804.md) | [0.4 d](/filings/0001193125-26-336725.md) | [0.5 d](/filings/0001193125-25-268095.md) | [0.5 d](/filings/0001193125-26-094013.md) | [1.2](/filings/0001193125-26-222804.md) | [0.8 d](/filings/0001193125-26-336725.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0000950170-23-061144.md) | [43.5](/filings/0000950170-24-055691.md) | [43.5](/filings/0000950170-24-089320.md) | [43.9](/filings/0000950170-24-122330.md) | [45.7](/filings/0000950170-25-069237.md) | [50.6](/filings/0001193125-25-174953.md) | [50.8](/filings/0001193125-25-268095.md) | [51.4](/filings/0001193125-26-222804.md) | [51.5](/filings/0001193125-26-336725.md) | [51.7](/filings/0001193125-25-268095.md) | [52.4](/filings/0001193125-26-222804.md) | [53.0](/filings/0001193125-26-336725.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 66,013,192 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-336725.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.